Cargando…

Advances in Multiple Sclerosis Research–Series I

Designing immunotherapeutics, drugs, and anti-inflammatory reagents has been at the forefront of autoimmune research, in particular, multiple sclerosis, for over 20 years. Delivery methods that are used to modulate effective and long-lasting immune responses have been the major focus. This Special I...

Descripción completa

Detalles Bibliográficos
Autores principales: Apostolopoulos, Vasso, Matsoukas, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692630/
https://www.ncbi.nlm.nih.gov/pubmed/33137992
http://dx.doi.org/10.3390/brainsci10110795
_version_ 1783614556829908992
author Apostolopoulos, Vasso
Matsoukas, John
author_facet Apostolopoulos, Vasso
Matsoukas, John
author_sort Apostolopoulos, Vasso
collection PubMed
description Designing immunotherapeutics, drugs, and anti-inflammatory reagents has been at the forefront of autoimmune research, in particular, multiple sclerosis, for over 20 years. Delivery methods that are used to modulate effective and long-lasting immune responses have been the major focus. This Special Issue, “Advances in Multiple Sclerosis Research—Series I”, focused on delivery methods used for immunotherapeutic approaches, drug design, anti-inflammatories, identification of markers, methods for detection and monitoring MS and treatment modalities. The issue gained much attention with 20 publications, and, as a result, we launched Series II with the deadline for submission being 30 April 2021.
format Online
Article
Text
id pubmed-7692630
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76926302020-11-28 Advances in Multiple Sclerosis Research–Series I Apostolopoulos, Vasso Matsoukas, John Brain Sci Editorial Designing immunotherapeutics, drugs, and anti-inflammatory reagents has been at the forefront of autoimmune research, in particular, multiple sclerosis, for over 20 years. Delivery methods that are used to modulate effective and long-lasting immune responses have been the major focus. This Special Issue, “Advances in Multiple Sclerosis Research—Series I”, focused on delivery methods used for immunotherapeutic approaches, drug design, anti-inflammatories, identification of markers, methods for detection and monitoring MS and treatment modalities. The issue gained much attention with 20 publications, and, as a result, we launched Series II with the deadline for submission being 30 April 2021. MDPI 2020-10-29 /pmc/articles/PMC7692630/ /pubmed/33137992 http://dx.doi.org/10.3390/brainsci10110795 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Editorial
Apostolopoulos, Vasso
Matsoukas, John
Advances in Multiple Sclerosis Research–Series I
title Advances in Multiple Sclerosis Research–Series I
title_full Advances in Multiple Sclerosis Research–Series I
title_fullStr Advances in Multiple Sclerosis Research–Series I
title_full_unstemmed Advances in Multiple Sclerosis Research–Series I
title_short Advances in Multiple Sclerosis Research–Series I
title_sort advances in multiple sclerosis research–series i
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692630/
https://www.ncbi.nlm.nih.gov/pubmed/33137992
http://dx.doi.org/10.3390/brainsci10110795
work_keys_str_mv AT apostolopoulosvasso advancesinmultiplesclerosisresearchseriesi
AT matsoukasjohn advancesinmultiplesclerosisresearchseriesi